References
- Clark C, Schneider JA, Mintun MA et al.; AV45-A07 Study Group. Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study. Alzheimers Dement.6(4 Suppl.), S71 (2010).
- Doody RS, Tariot P, Cummings J et al. Results from CONNECTION: a global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer’s disease. Alzheimers Dement.6(4 Suppl.), S147 (2010).
- Craft S, Baker LD, Green PS et al. A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer’s. Alzheimers Dement.6(4 Suppl.), S587 (2010).
- Eriksdotter Jonhagen M. Local delivery of NGF to basal forebrain in AD patients. Alzheimers Dement.6(4 Suppl.), S147–S148 (2010).
- Sager MA, Lawrence B, La Rue A. The Wisconsin memory screening initiative: rationale and results. Alzheimers Dement.6(4 Suppl.), S323–S324 (2010).
- Schneider LS, Kennedy RE, Cutter G. Requiring a CSF amyloid-β42 biomarker for a prodromal AD research diagnosis does not result in better clinical trials: simulations from the ADNI database. Alzheimers Dement.6(4 Suppl.), S100 (2010).
Websites
- McCarten JR, Anderson P, Kuskowski MA, Jonk Y, Dysken MW. Changes in outpatient costs following screening and diagnosis of cognitive impairmentwww.alz.org/icad/documents/abstracts/2010_early_detection.pdf
- Zhu C, Sano M, Ferris S, Aisen P. Assessing health related resource use in normal elders and subjects with mild cognitive impairmentwww.alz.org/icad/documents/abstracts/2010
- Alzheimer’s Association recommendations to update diagnostic criteriawww.alz.org/research/diagnostic_criteria/